ABIONYX Pharma presents preclinical results for CER-001 in Brain Fog, at the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023
23 Novembro 2023 - 3:38PM
Business Wire
- CER-001 treatment attenuated systemic inflammation,
downregulated Indoleamine-2,3-dioxygenase (IDO1) thereby reducing
neuroactive metabolites and waste accumulation
- Preclinical data support the concept that the use of CER-001
may have the potential to enhance renal and cognitive
function
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, announces the presentation
of new preclinical data for CER-001 in the treatment of brain
dysfunction associated with acute kidney injury at the 1st
International Congress on brain-kidney interaction: from physiology
to clinics, to be held from November 23 to 24, 2023 in Naples,
Italy.
This lecture presentation follows the presentation of
preclinical results on the effects of CER-001 in brain dysfunction
induced by acute kidney injury, which were the subject of a
dedicated poster at the 2023 Annual Meeting of the American Society
of Nephrology (ASN) held from November 2 to 5, 2023, as part of
Kidney Week.
To date there are no appropriate preventive or therapeutic
solutions to treat brain dysfunction related to kidney injury
consecutive or concomitant with sepsis.
A preclinical study has been sponsored by ABIONYX Pharma to
assess the effects of recombinant apoA‑I phospholipid complexes in
reducing the inflammatory process and preventing sepsis-induced
acute renal failure and brain dysfunction.
In both CER-001 dose groups (20 mg/kg and 2x20 mg/kg), blood
samples showed a significant reduction in
Indolamine-2,3-dioxygenase enzyme activity, measured as the
kynurenine/tryptophan ratio (p<0.05) and quinolinic acid levels
(p<0.005) compared with the untreated control group. In
addition, a significant decrease in systemic and brain
interleukin-6 (IL-6) levels was observed after CER‑001
treatment.
Taken together, these data indicate that CER-001 treatment can
reduce the inflammatory response, retention of residual substances
and neuroactive compounds, thereby potentially improving renal and
cognitive function in sepsis-induced acute renal failure. These
results pave the way for future clinical trials in potential
additional indications, such as neuropsychiatric lupus or, more
importantly long Covid.
Prof. Loreto Gesualdo, Head of the Unit of Nephrology,
Dialysis and Transplantation at the University of Bari Aldo Moro in
Italy, and principal investigator of the RACERS study,
comments: "Following our exclusive presentation of robust data
in sepsis at the ASN in early November, the results obtained in
Brain Fog demonstrate the broad spectrum of efficacy of CER-001,
one of the world's most advanced biologics. The unique properties
conferred by recombinant apoA-I lipoprotein complexes appear to
potentially reduce kidney and brain disorders in patients suffering
from sepsis. Taken together, these data support the clinical
development of CER-001 in potential new indications affecting the
gut-kidney-brain axis".
Session: oral presentation, 3:30 pm, November 24, 2023
Lecture title: Gut-Brain-Kidney: the stunning interplay
About Brain Fog
Brain fog is a set of symptoms describing a decline in the
quality of mental functioning. Numerous previous studies suggest
that partial convalescence following sepsis-induced acute renal
failure can have long-term consequences predisposing to chronic
dysfunction and accelerated neurocognitive decline in patients.
There is a close relationship between kidney damage and cerebral
dysfunction, even after the effects of acute sepsis-induced renal
failure have subsided, leading to severe wakefulness.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231123575364/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024